Understanding immunE-related toXicities by multifACeT Profiling

Recruiting now

Conditions studied: Oncology

In brief

A prospective observational cohort study of patients undergoing CPI therapy in which translational research is the fundamental aspect of the study.

Key facts

Study ID

NCT05331066

Run by

Royal Marsden NHS Foundation Trust

People needed

200

Starts

2022-04-06

Expected to finish

2028-04-06

Last updated by the study team

2025-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent
• Age 18 years or older
• Confirmed diagnosis of any form of solid malignancy with a clinical indication and appropriate treatment plan to commence immune checkpoint inhibitor therapy

You may not qualify if…

• Medical or psychological condition that would preclude informed consent
• Planned participation in a drug trial receiving investigational agents
• Subjects who have previously commenced immune checkpoint inhibitor therapy prior to study entry.
• Subjects unable to comply with the study or sample schedule.

Where it is running

• Royal Marsden NHS Foundation Trust — Chelsea, London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.